


MEDICINAL PRODUCTS 2023

Intellia Therapeutics Inc. Rank 15 of 48











Intellia Therapeutics Inc. Rank 15 of 48

The relative strengths and weaknesses of Intellia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intellia Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Intellia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 91% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	1,216,797
Assets, Non-Current	234,869
General and Administrative Expense	90,306
Goodwill	0
Liabilities, Current	126,554
Liabilities, Non-Current	0
Other Assets	40,527
Other Compr. Net Income	-4,829
Other Expenses	0
Other Liabilities	0
Other Net Income	-16,022
Other Revenues	52,121
Property, Plant and Equipment, Net	27,921
Research and Development	419,979

Output Variable	Value in 1000 USD
Liabilities	126,554
Assets	1,520,114
Expenses	510,285
Revenues	52,121
Stockholders Equity	1,393,560
Net Income	-474,186
Comprehensive Net Income	-476,600
Economic Capital Ratio	86%

